Payment overview · 2025
General Payments
$308.22
8 reported records · 5 companies
Healthcare provider profile · identity verified
Carl Casimir, M.D., D.O
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1710068721
Verified facts
What the public records show
CMS Open Payments records show Carl Casimir, M.D., D.O received $308.22 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 42.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synjardy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $132.25 | 42.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $68.96 | 22.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.98 | 18.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.71 | 8.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.32 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $308.22 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $118.42 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $68.96 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.98 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.71 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.71 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.71 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 111 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 160 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
111 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 683 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 546 | 155 |
| Metformin Hcl | Metformin Hcl | 405 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 276 | 69 |
| Nifedipine Er | Nifedipine | 275 | 75 |
| Losartan Potassium | Losartan Potassium | 273 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 76 |
| Gabapentin | Gabapentin | 225 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 63 |
| Meloxicam | Meloxicam | 186 | 96 |
| Januvia | Sitagliptin Phosphate | 176 | 34 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 167 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 165 | 41 |
| Jardiance | Empagliflozin | 160 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 160 | 45 |
| Donepezil Hcl | Donepezil Hcl | 156 | 37 |
| Simvastatin | Simvastatin | 140 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 41 |
| Furosemide | Furosemide | 128 | 38 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 122 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 37 |
| Mirtazapine | Mirtazapine | 117 | 25 |
| Farxiga | Dapagliflozin Propanediol | 111 | 26 |
| Lisinopril | Lisinopril | 111 | 29 |
| Glimepiride | Glimepiride | 109 | 31 |
| Alendronate Sodium | Alendronate Sodium | 108 | 33 |
| Enalapril Maleate | Enalapril Maleate | 106 | 30 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 104 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 103 | 36 |
| Omeprazole | Omeprazole | 102 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 45 |
| Valsartan | Valsartan | 90 | 23 |
| Eliquis | Apixaban | 88 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 42 |
| Vascepa | Icosapent Ethyl | 81 | 15 |
| Labetalol Hcl | Labetalol Hcl | 79 | 21 |
| Glipizide | Glipizide | 78 | 25 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 78 | 22 |
| Glipizide Er | Glipizide | 70 | 21 |
| Tradjenta | Linagliptin | 68 | 13 |
| Finasteride | Finasteride | 67 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 66 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 22 |
| Ezetimibe | Ezetimibe | 65 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 65 | 20 |
| Single Use Swab | Alcohol Antiseptic Pads | 58 | 32 |
| Atenolol | Atenolol | 57 | 19 |
| Carvedilol | Carvedilol | 57 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 17 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 48 | 15 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 45 | 21 |
| Azithromycin | Azithromycin | 43 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 43 | 12 |
| Novolog Flexpen | Insulin Aspart | 42 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 15 |
| Alcohol Swab | Alcohol Antiseptic Pads | 37 | 19 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 35 | 16 |
| Dutasteride | Dutasteride | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 11 |
| Famotidine | Famotidine | 32 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 28 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 30 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Repaglinide | Repaglinide | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 11 |
| Jentadueto | Linagliptin/Metformin Hcl | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | 14 |
| Ammonium Lactate | Ammonium Lactate | 24 | 17 |
| Fluocinonide | Fluocinonide | 24 | 12 |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 21 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Leflunomide | Leflunomide | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 17 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 17 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 12 |
| Ozempic | Semaglutide | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Naproxen | Naproxen | 15 | 14 |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $308.22 · 8 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, FARXIGA, JARDIANCE, Kerendia, Ozempic, PREVNAR 20, Rybelsus, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error